Fintel reports that on April 8, 2025, Goldman Sachs initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

Goldman Sachs launched its coverage of Viking Therapeutics (NASDAQ:VKTX) with a Neutral recommendation and a $30 per share target on Tuesday, arguing that competitive headwinds in the weight loss drug ...

Goldman Sachs analyst Richard Law initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $30 price target The company’s ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against other stocks that are skyrocketing today. The stock market ended mixed on Wednesday ...

Assess the potential risks impacting Viking Therapeutics' growth trajectory—explore our risk evaluation report. NasdaqCM:VKTX Earnings Per Share Growth as at Mar 2025 Diversify your portfolio ...

Viking Therapeutics (NasdaqCM:VKTX) has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the ...

Shares of Viking Therapeutics (NASDAQ:VKTX) have plunged since my November 2024 update and since I removed the stock from our Growth Stock Forum's model portfolio. My stated reasons for removal ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus rating of “Buy” by the thirteen research firms that are covering the firm, MarketBeat reports. One investment ...